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Abstract
Background Desmin-related myopathy (DRM) is an autoso-
mally inherited skeletal and cardiac myopathy, mainly caused
by dominant mutations in the desmin gene (DES). We describe
new families carrying the p.S13F or p.N342D DES mutations,
the cardiac phenotype of all carriers, and the founder effects.
Methods We collected the clinical details of all carriers of p.
S13F or p.N342D. The founder effects were studied using
genealogy and haplotype analysis.
Results We identified three new index patients carrying the
p.S13F mutation and two new families carrying the p.N342D
mutation. In total, we summarised the clinical details of 39 p.
S13F carriers (eight index patients) and of 21 p.N342D
carriers (three index patients). The cardiac phenotype
of p.S13F carriers is fully penetrant and severe, characterised
bycardiacconductiondiseaseandcardiomyopathy,oftenwith
right ventricular involvement. Although muscle weakness is a
prominent and presenting symptom in p.N342D carriers, their
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Conclusion DRM may occur as an apparently isolated
cardiological disorder. The cardiac phenotypes of the DES
founder mutations p.S13F and p.N342D are characterised by
cardiac conduction disease and cardiomyopathy, often with
right ventricular involvement.
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Introduction
Mutations in the gene encoding desmin (DES), a major inter-
mediate filament protein of skeletal and cardiac muscle, are
the main cause of desmin-related myopathy (DRM, OMIM
#601419) [1, 2]. The desmin protein provides structural and
functional integrity by coordinating mechanical stress trans-
mission, organelle positioning and assembly of sarcomeres,
signal transduction, and apoptosis [3]. DRM’sc l i n i c a lp h e n o -
type encompasses myopathies, cardiomyopathies, cardiac
conduction disease, and combinations of these disorders.
More than 50 different DES mutations have been identified
worldwide; most of these are inherited missense mutations,
mainly located in the 2B domain of the protein (Fig. 1).
Potentialgenotype-phenotyperelationships are now emerging
[4]. Desmin-immunoreactive deposits in skeletal and cardiac
muscles and granulofilamentous material at the ultrastructural
level are considered morphological hallmarks of DRM [5].
Recently, we performed a meta-analysis of 159 DES
mutation carriers with 40 different mutations, focusing on
their clinical characteristics [4]. Both neurological and
cardiological signs were present in 48% of carriers, whereas
isolated neurological or isolated cardiological signs were
each present in 22%. Up to 50% of carriers had cardiomy-
opathy, with dilated cardiomyopathy being most prevalent.
In 62% cardiac conduction disease and/or arrhythmias were
reported, with the most frequent being atrioventricular
block. Symptoms started at a mean age of 35 years (range
11–72 years), while a quarter of carriers had died at a mean
age of 49 years (range 28–62 years). Only 5 out of 159
carriers (three women aged between 39–54 years and two 5-
year-old children) showed no phenotype at the time of
evaluation [4].
In the Netherlands, two DES mutations (p.S13F and p.
N342D) have been identified in several index patients. We
have previously described some of these families [6–8]. For
the current study, we were able to extend these data with
new families/patients and additional information on the
cardiac phenotypes of previously published patients. Our
aims were (1) to describe new families carrying the p.
S13F or p.N342D DES mutations, (2) to investigate the
cardiac phenotype of all known Dutch patients and carriers
described in the literature, and (3) to study the founder
effects of the two mutations in the Netherlands.
Methods
Mutation analysis
Since 2004 two clinical genetics centres (at Maastricht
University Medical Centre and University Medical Center
Groningen) perform genetic screening for DES in the
Netherlands. Genomic DNAwas isolated from blood samples
obtained from the index patients and relatives using stand-
ardised procedures. Analysis of DES was performed accord-
ing to the method we have described previously [9]. Written
informed consent was obtained from DES mutation carriers
according to the hospitals’ medical ethics committees.
Clinical evaluation
We collected data from cardiological evaluation (12-lead
ECG, echocardiography, 24-hour Holter monitoring, and
exercise testing) fromall evaluated known and obligate Dutch
carriers (35 with p.S13F and 19 with p.N342D). Some of
these data have been described previously [6–8]. We were
able to extend these data with new patients/families and extra
information on the cardiac phenotype of previously published
patients.IfonlyECGandX-ray oftheheartwereavailablewe
consider cardiac enlargement to be a cardiomyopathic feature
if these individuals also had indications of cardiac conduction
disorders. We have also summarised the published cardiolog-
ical data on p.S13F and p.N342D carriers of other origin.
Genealogy
To discover possible distant relationships between index
patients, the genealogies were investigated using civil regis-
ters and state archives. The pedigrees were reconstructed to
approximately AD 1750 (covering 6–8 generations).
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Fig. 1 Schematic representation of desmin with locations of p.S13F
(‘head’ structure) and p. N342D (2B domain). The desmin molecule is
organised in three domains: a highly conserved alpha-helical core (with
four consecutive helical rod segments (domain 1A, 1B, 2A, and 2B)
connected by short non-helical linkers) flanked by globular N- and C-
terminal (‘head’ and ‘tail’) structures
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Ten microsatellite markers around DES were selected with
the National Center for Biotechnology Information (NCBI)
Map Viewer and analysed in carriers and control persons
(primers and conditions available upon request).
Geographical distribution of carriers
We mapped the geographical distribution of proven (n024
and n012 respectively) and obligate/likely carriers (n02a n d
n013 respectively) of p.S13F or p.N342D in the Netherlands
by collecting the postal codes. For each mutation, the data
were converted into an overview of the postal code areas.
These make up 90 different regions, each containing about
180,000 inhabitants.
Results
Yield of mutation analyses of the DES gene
in the Netherlands
Five different pathogenic mutations in DES have been iden-
tified in the Netherlands, resulting in the following changes
at the protein level: p.S13F, p.N342D, p.R454W, p.T442I,
and p.T453I (Table 1). Previously, we published on p.S13F,
p.N342D, and p.R454W [6–8]. The two other mutations
(p.T442I and p.T453I) have been newly identified in the
Netherlands, each in one index patient, but they have been
described in the literature (Table 1)[ 10, 11]. We also found
several variants in DES that are unclassified, or which seem
to be a modifier or polymorphism, resulting in the following
changes at the protein level: p.G27S, p.L136L, p.A213V,
p.A285V, p.R315H, p.N342N. In addition, the following
intronic and 3’UTR variants were identified: c.578+11 G>A,
c.735+20 C>T and c.*468 C>T.
In this study we focused on the two Dutch founder muta-
tions (p.S13F and p.N342D). Mutation p.S13F (c.38 C>T) is
a missense mutation in the head domain (Fig. 1). Mutation p.
N342D (c.1024A>G) is a missense mutation in the 2B do-
main (Fig. 1). Both mutations alter highly conserved residues,
changepolarity,co-segregatewithdiseaseinthefamiliesofall
identified index patients, and were absent in at least 300
ethnically matched control alleles. Twenty-seven proven and
eight obligate p.S13F carriers were identified by family cas-
cade screening of eight index patients. Twelve proven and
seven obligate p.N342D carriers were identified by family
cascade screening of three index patients.
Cardiac phenotype of p.S13F
We collected the clinical characteristics from three new
index patients (F-III-1, G-III-1, H-III-1; Table 2)w i t ha
family history suspected for DRM (Fig. 2). We also
gathered additional information (echocardiography and
new electrocardiogram) on one previously published pa-
tient (E-I-2; Table 2) and cardiological findings on three
newly identified carriers in a previously described family
(D-II-7, D-III-3, D-III-4; Table 2). For information on the
clinical characteristics of previously published individu-
als and their pedigrees, see Table 1 and Fig. 1 from our
previous study [8]. One of the previously published patients
(C-VII-10) died at the age of 48, but we have no details about
the course of events leading to death. In total, 35 known and
obligate p.S13F carriers (including eight index patients) have
now been identified and clinically evaluated in the Nether-
lands (June 2011).
We have summarised our Dutch data together with the
data published on four Singapore-Chinese p.S13F carriers [12]
(Table 2). Many patients show a severe cardiac phenotype,
Table 1 Overview of 5
pathogenic DES mutations
identified in the Netherlands and
literature references
Mutation References Familial Ethnicity Founder / de novo Remarks
p.S13F 6,8 5 families Dutch Founder
This article 3 families Dutch Founder
12 1 family Chinese Different haplotype to
Dutch founder
p.N342D This article 2 families Dutch Founder
7 1 family Dutch Founder
1,14 1 family Irish-German De novo
p.R454W 7 1 family Dutch
11 1 patient North African De novo Additional MYOT mutation
p.T442I 11 1 family French
This article 1 patient Dutch
p.T453I 10 1 patient Italian? De novo
This article 1 patient Dutch De novo
Neth Heart J (2012) 20:219–228 221including sudden cardiac death or progressive heart failure: 14
of 39 known and obligate carriers died, underwent transplan-
tation, or experienced appropriate implantable cardioverter
defibrillator (ICD) interventions at a mean age of 48.4 years
(range 27–63 years). Data on initial presentation were avail-
able on 31/39 carriers, all of whom had a cardiac phenotype:
21/31 individuals (68%) presented initially with a cardiac
phenotype, five individuals (16%) presented with cardiologi-
cal symptoms preceding neuromuscular symptoms, while the
other five individuals (16%) presented with neuromuscular
symptoms before or simultaneously with cardiac pathology.
Thus, more than 80% presented with isolated cardiological
symptoms. We had information on the cardiomyopathic
phenotypeavailablefor28carriers:17/28(61%)haddeveloped
a cardiomyopathic phenotype: nine dilated cardiomyopathy;
five left ventricular hypertrophy, diastolic dysfunction,
or a restrictive cardiomyopathy-like phenotype; one had
an unspecified form of cardiomyopathy; and two had
arrhythmogenic right ventricular cardiomyopathy (ARVC). In
addition to these ARVC patients, right ventricular involvement
was noticeable due to right ventricular failure in six other
patients,andventriculartachycardiasoriginatingfromtheright
ventricle in two patients. Furthermore, as many as 13 patients
showed right bundle branch block (RBBB) which also sug-
gests involvement of the right ventricle, although this remains
speculative. Regarding the electrocardiographic data from 31
carriers: 21/31 (68%) demonstrated RBBB, left bundle branch
block, or atrioventricular block at the time of initial presenta-
tion (Fig. 3), suggesting that this is an early manifestation of
the disease.
Table 2 Clinical characteristics of p.S13F carriers, patient ID of new index patients in bold
Patient
ID
M/F Genetic
status
Referred
for (age)
Cardiologic:
ECG/rhythm (age)
Cardiologic:
Structural (age)
Neuromuscular
phenotype:
Myopathy (age)
Outcome/follow-up
(age)
D-II-7
8 F p.S13F collapse (55) RBBB, cAVB, LAHB (55) normal (56) iliopsoas, CK 237 (57) PM (55)
D-III-3
8 M p.S13F screening (37) PVCs, IVCD (37) normal (37) no MW, CK 782 (37)
D-III-4
8 F p.S13F screening (32) IVCD (32) normal (32) normal (33)
E-I-2
8 F p.S13F MW (54) incomplete RBBB (62),
incomplete RBBB,
borderline first-degree
AVB, LAHB (71)
normal (71) distal, CK normal
(54)
F-III-1 M p.S13F
(index)
arrhythmias (32) PACs, AVNRT, AVB,
RBBB(32); cAVB
(36); atrial flutter (42)
DCM with severe
LVand RV
dysfunction (42)
MW (28), limb-girdle,
CK 400-800 (38)
PM (36); wheel chair
(42); D heart failure
(43)
G-III-1 M p.S13F
(index)
Effort-related chest
discomfort (37)
SSS, NSVTs, PVCs,
RBBB, LAHB,
intermittent first-
and second-degree
AVB (37); cAVB
DCM with moderate
LVand severe
RVdysfunction (49)
mild shoulder-girdle
(52)
PM (37), recurrent
presyncope (48, 49),
collapse (49), ICD
(50), ICD/CRT (52);
HTX waiting list
(52)
H-III-1 F p.S13F
(index)
collapse (36) cAVB (36) normal (36); mild
LVdysfunction (38)
mild iliopsoas (38) PM (36); ICD (40)
H-III-2 F p.S13F screening (33) IVCD (33) normal (33) no weakness (33)
H-IV-2 M p.S13F screening (9) PVCs, LBBB (9) NA (pending) no weakness (9)
P-I-2
12 F p.S13F screening NA NA very mild proximal
and distal, CK 270
P-II-2
12 F p.S13F screening NA NA very mild proximal
and distal, CK 270
palpitations
P-II-3
12 M p.S13F
(index)
collapse (39) cAVB (39) normal (39) mild proximal and
distal limb, CK
1028 (39)
PM (39)
P-II-4
12 M p.S13F screening NA NA mild proximal and
distal limb, CK
1125
syncope
Ages are given in years in brackets. Abbreviations: AVNRT AV nodal re-entry tachycardia, (c)AVB (complete) atrioventricular block, CK creatine
phosphokinase (in U/L), DCM dilated cardiomyopathy, ECG electrocardiogram, F female, HTX heart transplantation, ICD implantable cardioverter
defibrillator, IVCD intraventricular conduction defect, LAHB left anterior hemi block, LV left ventricle, M male, MW muscular weakness, NA no
information available, NSVT non-sustained ventricular tachycardia, PM pacemaker, PAC premature atrial contraction, PVC premature ventricular
contraction, RBBB right bundle branch block, RV right ventricle, SSS sick sinus syndrome
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Common ancestors for three index patients (from families
A, B, and C) were previously revealed by their genealogy
[8]. Additional genealogical investigations revealed several
links between all eight index patients. Haplotype analysis
demonstrated an identical haplotype for six microsatellite
markers in carriers of the available (7/8) Dutch families (see
online supplement). Analysis revealed a different haplotype
in a Singapore-Chinese p.S13F carrier (individual Pica II-3)
[12] (see online supplement).
Cardiac phenotype of p.N342D
In 1975 two large Dutch families with “inflammatory myop-
athy in scapulo-ilio-peroneal atrophy with cardiopathy” were
reported [13]. We identified a p.N342D mutation in these
families, thereby proving that these families had DRM. Fig-
ure 4 shows updated pedigrees for these families. In total, 19
known and obligate p.N342D and 10 probable carriers (in-
cluding three index patients) have now been identified and
clinically evaluated in the Netherlands. See Table 3 for the
clinicalcharacteristics.Thedatasummarybelowisbasedonly
on the known and obligate carriers. For the pedigree offamily
A, we refer to Fig. 1 from a previous publication [7].
We summarised our data together with that published on
two p.N342D carriers of Irish-German decent [1, 14]. Data on
presentation were available from 17 carriers: they all pre-
sented with neuromuscular symptoms (16 weakness of
muscles,onepainfulcalves),onlyoneindividualwasreported
to have cardiac complaints (palpitations) simultaneously with
neuromuscular symptoms. The mean age at presentation was
29.6 (range 16–42 years). We had information on cardiomyo-
pathic phenotype for 11 carriers: 6/11 (55%) had a cardio-
myopathic phenotype: three cardiac enlargement (not further
specified), one left ventricular dysfunction, one ARVC, and
one left ventricular hypertrophy. We had electrocardiographic
data available for 18 carriers: 13/18 showed abnormalities on
ECG, 10 (63%) of them had cardiac conduction disease.
RBBB was identified in four patients.
Genealogy and haplotype analysis of families with p.N342D
Genealogy revealed a common ancestral couple for families
O and A, but no link between families O and U. Haplotype
analysis around DES revealed an identical haplotype for
eight microsatellite markers in carriers from all three Dutch
families (see online supplement).
Geographical distribution of carriers of p.S13F or p.N342D
Figure 5 shows the geographical distribution of known,
obligate and likely carriers of p.S13F (n026) or p.N342D
III:1
E: S13F
PM 36 y
LGMD 38 y
DCM 42 y
D 43 y
II:2
PM 63 y
II:4
PM 36 y
I:2
D 80 y 
PM
I:1
D 80 y 
PM 
Family F
III:1
E: S13F
PM 37 y
collapse 49 y
DCM 49 y
ICD 50 y
II:1
PM 20 y
heart disease
muscle weakness
D 54 y
II:2
D 28 y
I:2
D 54 y 
‘rheumatic’ heart disease
wheel chair
III:2
E: -
Family G
I:2
PM 42 y , collapse
probably cAVB
cardiac enlargement 75 y
D 76 y
III:1
E: S13F
cAVB, collapse, PM 36 y
mild LV dysfunction 38 y
II:4
PM 28 y, collapse
D 38 y
I:1
D 51 y
heart, embolism?
III:2
E: S13F
IV:2
E: S13F
PVCs, LBTB 9 y
IV:1
E:  -
II:3
E:  -
II:2
E:  -
Family H
Fig. 2 Pedigrees of three recently identified index patients with mutation
p.S13F. Square symbols indicate men, circles women. Black solid sym-
bols: clinical diagnosis DRM; half-closed symbols (vertical bar) indicate a
possible diagnosis of DRM, dots indicate mutation carriers. Diagonal lines
through symbols indicate the patient has died, arrow indicates index
patient in each family. Abbreviations: (c)AVB0(complete) atrioventricular
block, D0death, DCM0dilated cardiomyopathy, E: S13F0carrier of
p.S13Fmutation, E: -0not acarrierofp.S13F mutation,ICD0implantable
cardioverter defibrillator, LBTB0left bundle branch block, LGMD0
limb-girdle muscular dystrophy, LV0left ventricle, PM0pacemaker,
PVC premature ventricular contraction, y0years
Neth Heart J (2012) 20:219–228 223(n025) in the Netherlands (Fig. 5a, b), with the number of
such carriers per region. Each region contains on average
180,000 inhabitants. The geographical distribution of these
mutation carriers reflects the founder effect of both mutations,
although a difference in physicians’ knowledge of DRM and
in their referral for DES analysis might also have affected this
distribution (Fig. 5).
Discussion
We summarise the cardiac phenotypes of all carriers of two
Dutch DES founder mutations (p.S13F and p.N342D), in-
cluding three new index patients with p.S13F and two new
large families with p.N342D. This is the largest series to
date of carriers of single DES mutations.
The cardiac phenotype of p.S13F seems to be fully pene-
trant and is characterised by cardiomyopathy and cardiac
conduction disorders and/or arrhythmias, including right
ventricular involvement and atrioventricular block at a young
age. Most patients present with cardiological symptoms and/
or signs, compatible with conduction disease/arrhythmias
or cardiomyopathy/heart failure. Severe expression of the
cardiac phenotype, including sudden cardiac death or
progressive heart failure, is seen frequently. Neuromuscular
symptoms are not always present. In our series even the
youngest patient (H-IV-2 with cardiac evaluation at age 9)
already showed some cardiac conduction abnormalities. But
clinicians have to be aware that the penetrance is age depen-
dent, thus carriers can also develop their first cardiac abnor-
malities at a later age.
The cardiac phenotype of p.N342D is in accordance
with the phenotype of p.S13F. However, the neuromuscu-
lar phenotype is more prominent in carriers with p.N342D
than in those with p.S13F, because all p.N342D carriers
presented with a neuromuscular phenotype. Unfortunately,
we did not have full information on the severity of heart
failure or the exact causes of death of some p.N342D
carriers. The type of rhythm and conduction disorders
and the young ages at death in many individuals suggest
that the cardiac phenotype is also severe. But in some
cases respiratory problems seem to have been the cause
of death. Five p.N342D carriers (5/18, aged between 21-
30 years) did not show cardiological abnormalities at the
time of evaluation, but they may have developed a cardiac
phenotype at a later age. Thus full (age dependent) pene-
trance of the cardiac phenotype of p.N342D cannot be
excluded.
Fig. 3 A 12-lead electrocardiogram with RBBB (a) and a rhythm strip with high-grade atrioventricular block (b) from patients with p.S13F
224 Neth Heart J (2012) 20:219–228Table 3 Clinical characteristics of known and obligate p.N342D carriers and relatives likely to be carrier
Patient
ID
M/F Genetic
status
Referred
for (age)
Cardiologic:
ECG/rhythm (age)
Cardiologic:
Structural (age)
Neuromuscular
phenotype:
Myopathy (age)
Outcome/
follow-up (age)
O-II-5 M OC MW (42) AF, PVCs, LAHB cardiac enlargement scapulo-ilio-peroneal,
bulbar, neck
flexors (53)
D (53)
O-II-6 M OC MW (32) AF, PVCs, cAVB cardiac enlargement scapulo-ilio-peroneal,
bulbar, neck flexors
(50)
D (52)
O-III-1 F Likely MW (33) Repolarisation
abnormality
NA scapulo-ilio-peroneal
(35)
O-III-4 F OC MW (32) RBBB NA scapulo-ilio-peroneal,
bulbar, neck flexors
(36)
D (45)
O-III-6 F Likely NA PVCs, repolarisation
abnormality
NA peroneal D (53)
O-III-12 F p.N342D MW (37) Repolarisation
abnormality (63)
LV hypertrophy
(63)
bent spine,
scapuloperoneal (52)
O-III-13 F OC MW (21) normal NA scapulo-ilio-peroneal,
bulbar (27)
D (52)
O-III-14 M p.N342D MW (23) repolarisation abnormality
(24); atrial rhythm,
incomplete RBBB (41);
PACs, RBBB (43)
cardiac enlargement peroneal,
bulbar (23)
D possibly
MI (54)
O-III-15 F p.N342D MW (38) atrial rhythm, repolarisation
abnormality (45); RBBB,
LAHB (51)
slight LA enlargement
(51)
MW (38)
O-IV-2 F p.N342D
(index)
MW (27) RBBB (45) normal (45) bulbar, neck flexors,
ilioperoneal (38)
O-IV-9 F p.N342D MW (23) normal (35) normal (35) bulbar, neck flexors,
scapiloperoneal (34)
U-II-3 F likely MW (40) PACs, PVCs, RBBB,
first-degree AVB, LAHB
cardiac enlargement scapulo-ilio-peroneal
(66)
D (74)
U-II-7 F OC MW (36) first-degree AVB, LAHB NA scapulo-ilio-peroneal,
neck flexors (53)
D (60)
U-III-1 M likely MW (21) RBBB LV hypertrophy ilio-peroneal (32) D
U-III-6 M likely MW (35) AF, VTs (46) RV>LV dysfunction
(46)
peroneal (35), later
scapulo-ilio-peroneal
PM (46); D
HF (65)
U-III-8 M likely MW (28) normal NA scapulo-ilio-peroneal
(33)
D (46)
U-III-12 M likely MW (21) junctional tachycardia,
RBBB, LAHB
cardiac enlargement scapulo-ilio-peroneal,
neck flexors (41)
D (44)
U-III-14 F p.N342D NA LAHB NA peroneal (29) D (44)
U-III-15 F p.N342D NA Repolarisation
abnormality (45)
NA scapulo-ileo-peroneal
(28)
D (53)
U-III-17 F p.N342D MW (16) PACs, PVCs, ventricular
bigeminy, NSVTs,
repolarisation
abnormality (23)
normal (31) scapulo-ileo-peroneal,
CK elevated (17)
D (38)
U-IV-3 M likely arrhythmias
(35)
VTs, RBBB, LAHB (35) NA scapulo-peroneal (37) PM (35); ICD
U-IV-4 M likely MW (32) normal normal ilio-peroneal
U-IV-5 M p.N342D
(index)
painful
calves (23)
NA NA ilio-peroneal, neck
flexors (29)
palpitations,
exertional
dyspnoea;
D (41)
U-IV-6 F likely MW (26) NA NA scapulo-ilio-peroneal,
neck flexors (35)
U-IV-9 F p.N342D MW (27) normal (29) normal (29) scapulo-ileo-peroneal
(29)
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Patient
ID
M/F Genetic
status
Referred
for (age)
Cardiologic:
ECG/rhythm (age)
Cardiologic:
Structural (age)
Neuromuscular
phenotype:
Myopathy (age)
Outcome/
follow-up (age)
A-II-1
7 M p.N342D
(index)
MW,
palpitations
(36)
AF (39); sinus arrests,
PVCs, first-degree
AVB, repolarisation
abnormalities (negative
Ts multiple leads),
epsilon wave (41);
VTs (42)
ARVC (42) leggs (36), later hand
and diaphragma
collapse,
resuscitation,
ICD (42)
A-II-2
7 M p.N342D MW (41) first-degree AVB (46) LV dysfunction (46) leggs (41)
D-I-3
1,14 F p.N342D
(index)
MW (30) normal NA distal, CK 364 (30),
later proximal
wheelchair (45)
D-I-4
1,14 M p.N342D MW (23) normal NA mild distal (23), CK
963 (25)
Ages are given in years in brackets. Abbreviations: AF atrial fibrillation, ARVC arrhythmogenic right ventricular cardiomyopathy, (c)AVB
(complete) atrioventricular block, CK creatine phosphokinase (in U/L), D death, ECG electrocardiogram, F female, HF heart failure, ICD
implantable cardioverter defibrillator, LA left atrium, LAHB left anterior hemi block, LV left ventricle, M male, MI myocardial infarction,
MW muscular weakness, NA no information available, NSVT non-sustained ventricular tachycardia, OC obligate carrier, PAC premature
atrial contraction, PM pacemaker, PVC premature ventricular contraction, RBBB right bundle branch block, RV right ventricle, VT
ventricular tachycardia
I
II
III
IV
V
I
II
III
IV
Family U
Family O
Fig. 4 Pedigrees of families O and U with mutation p.N342D.
Updated pedigrees of the two families (O and U) previously published
by Jennekens et al. [13] in which we identified mutation p.N342D.
Square symbols indicate men, circles women, diamonds unknown sex.
Black filled symbols: clinical diagnosis DRM. Diagonal lines through
symbols indicate deceased. The number in a symbol indicates the
number of individuals with this symbol
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types associated with these two DES mutations is the loca-
tion of the mutation. Mutations in the 2B domain such as p.
N342D are predominantly involved when patients have an
isolated neuromuscular phenotype, whereas head and tail
domain mutations are predominant in patients who have
an isolated cardiological phenotype [4]. Although the neu-
romuscular phenotype in carriers of the 2B domain mutation
p.N342D is more prominent compared with carriers of the
head mutation p.S13F, these mutations both cause cardio-
logical as well as neuromuscular signs.
From the literature, there are indications that ICD therapy
is better than pacemaker therapy for DES mutation carriers
in need of a pacemaker [4, 15]. Our study underscores this:
individual H-II-4 experienced several collapses despite hav-
ing a pacemaker and died suddenly without signs of heart
failure; individual G-III-1 collapsed despite a pacemaker
and received an ICD (no appropriate shocks in 2 years of
follow-up), and individual D-II-3 died suddenly 5 months
after he had received a pacemaker for a complete atrioven-
tricular block after cardiomyoplasty. Autopsy did not show
abnormalities related to cardiomyoplasty so that ventricular
fibrillation was suggested as the cause of death. However,
future studies are necessary to evaluate whether ICD therapy
is better than pacemaker therapy for DES mutation carriers
in need of a pacemaker.
Historically, it is possible that the founder mutation was
inherited from a person travelling with the Dutch East Indies
Company to Singapore or China in the 17th or 18th century.
But our analysis revealed a different haplotype in a p.S13F
carrier of the Singapore-Chinese family to that found in the
Dutch families. It is therefore unlikely that the mutation in the
Singapore-Chinese family is the same founder mutation. So
this is a recurrent mutation and it is possible that more carriers
of this particular mutation will be identified worldwide.
We are convinced that there are many unidentified car-
riers of p.S13F and p.N342D founder mutations in the
Netherlands. Our estimation of the number of unidentified
p.S13F carriers is several hundreds, taking into account that
the genealogical links between the identified families are
usually more than five generations ago and that death occurs
in the majority of cases after reproductive age. We hope this
study will lead to better recognition of the phenotype and
identification of carriers.
Recognition of DRM and identifying the underlying mu-
tation, followed by family cascade screening, is important.
DRM should be considered in patients with a combination
of skeletal myopathy and any type of cardiomyopathy (es-
pecially with right ventricular dysfunction) or cardiac con-
duction disease (especially atrioventricular block), but also
in patients with isolated cardiomyopathy or skeletal myop-
athy. Family H shows that DRM can even present as an
apparently isolated, familial cardiac conduction disorder.
We recommend paying attention to the family history and
referring patients to a cardiogenetics outpatient clinic. Early
diagnosis of DRM provides the opportunity to prevent com-
plications and reduce morbidity and mortality. We propose
regular cardiological monitoring of all DES mutation
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Fig. 5 Geographical distribution of carriers of p.S13F (A) and p.
N342D (B). The geographical distribution of known, obligate and
likely carriers of p.S13F (n026) and p.N342D (n025), respectively,
in the Netherlands, showing the number of carriers per home region (in
brackets: the number of regions). Each region contains on average
180,000 inhabitants
Neth Heart J (2012) 20:219–228 227carriers starting at the age of 10 years and we recommend
ICD therapy be considered instead of pacemaker therapy in
those carriers who need a pacemaker.
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